Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04151563
Title	A Phase 1/2 Study Evaluating Multiple Nivolumab Combination Therapy in Participants With Stage IV Non-small Cell Lung Cancer That Has Spread or Has Reoccurred After Failure of Chemotherapy and Immunotherapy
Acronym	CheckMate 79X
Recruitment	Withdrawn
Gender	both
Phase	Phase Ib/II
Variant Requirements	Yes
Sponsors	Bristol-Myers Squibb
Indications	lung non-small cell carcinoma
Therapies	Lucitanib + Nivolumab Docetaxel Cabozantinib + Nivolumab Cabozantinib + Ipilimumab + Nivolumab Docetaxel + Nivolumab Docetaxel + Nivolumab + Ramucirumab
Age Groups:	senior \| adult
Covered Countries	USA \| ROU \| POL \| NOR \| NLD \| GRC \| DNK \| BEL \| ARG